BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

548 related articles for article (PubMed ID: 29751762)

  • 1. HIV latency reversing agents act through Tat post translational modifications.
    Khoury G; Mota TM; Li S; Tumpach C; Lee MY; Jacobson J; Harty L; Anderson JL; Lewin SR; Purcell DFJ
    Retrovirology; 2018 May; 15(1):36. PubMed ID: 29751762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A New Quinoline BRD4 Inhibitor Targets a Distinct Latent HIV-1 Reservoir for Reactivation from Other "Shock" Drugs.
    Abner E; Stoszko M; Zeng L; Chen HC; Izquierdo-Bouldstridge A; Konuma T; Zorita E; Fanunza E; Zhang Q; Mahmoudi T; Zhou MM; Filion GJ; Jordan A
    J Virol; 2018 May; 92(10):. PubMed ID: 29343578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism.
    Boehm D; Calvanese V; Dar RD; Xing S; Schroeder S; Martins L; Aull K; Li PC; Planelles V; Bradner JE; Zhou MM; Siliciano RF; Weinberger L; Verdin E; Ott M
    Cell Cycle; 2013 Feb; 12(3):452-62. PubMed ID: 23255218
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.
    Laird GM; Bullen CK; Rosenbloom DI; Martin AR; Hill AL; Durand CM; Siliciano JD; Siliciano RF
    J Clin Invest; 2015 May; 125(5):1901-12. PubMed ID: 25822022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation.
    Li Z; Guo J; Wu Y; Zhou Q
    Nucleic Acids Res; 2013 Jan; 41(1):277-87. PubMed ID: 23087374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression.
    Darcis G; Kula A; Bouchat S; Fujinaga K; Corazza F; Ait-Ammar A; Delacourt N; Melard A; Kabeya K; Vanhulle C; Van Driessche B; Gatot JS; Cherrier T; Pianowski LF; Gama L; Schwartz C; Vila J; Burny A; Clumeck N; Moutschen M; De Wit S; Peterlin BM; Rouzioux C; Rohr O; Van Lint C
    PLoS Pathog; 2015 Jul; 11(7):e1005063. PubMed ID: 26225566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A chalcone derivative reactivates latent HIV-1 transcription through activating P-TEFb and promoting Tat-SEC interaction on viral promoter.
    Wu J; Ao MT; Shao R; Wang HR; Yu D; Fang MJ; Gao X; Wu Z; Zhou Q; Xue YH
    Sci Rep; 2017 Sep; 7(1):10657. PubMed ID: 28878233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
    Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
    J Virol; 2017 May; 91(9):. PubMed ID: 28202759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BET bromodomain inhibition as a novel strategy for reactivation of HIV-1.
    Banerjee C; Archin N; Michaels D; Belkina AC; Denis GV; Bradner J; Sebastiani P; Margolis DM; Montano M
    J Leukoc Biol; 2012 Dec; 92(6):1147-54. PubMed ID: 22802445
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Shutdown of HIV-1 Transcription in T Cells by Nullbasic, a Mutant Tat Protein.
    Jin H; Li D; Sivakumaran H; Lor M; Rustanti L; Cloonan N; Wani S; Harrich D
    mBio; 2016 Jul; 7(4):. PubMed ID: 27381288
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of an Attenuated Tat Protein as a Highly-effective Agent to Specifically Activate HIV-1 Latency.
    Geng G; Liu B; Chen C; Wu K; Liu J; Zhang Y; Pan T; Li J; Yin Y; Zhang J; Huang F; Yu F; Chen J; Ma X; Zhou J; Kuang E; Liu C; Cai W; Zhang H
    Mol Ther; 2016 Sep; 24(9):1528-37. PubMed ID: 27434587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Splicing Factor 3B Subunit 1 Interacts with HIV Tat and Plays a Role in Viral Transcription and Reactivation from Latency.
    Kyei GB; Meng S; Ramani R; Niu A; Lagisetti C; Webb TR; Ratner L
    mBio; 2018 Nov; 9(6):. PubMed ID: 30401776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alternate NF-κB-Independent Signaling Reactivation of Latent HIV-1 Provirus.
    Acchioni C; Remoli AL; Marsili G; Acchioni M; Nardolillo I; Orsatti R; Farcomeni S; Palermo E; Perrotti E; Barreca ML; Sabatini S; Sandini S; Parolin C; Lin R; Borsetti A; Hiscott J; Sgarbanti M
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31243131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
    Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
    Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Natural Product from Polygonum cuspidatum Sieb. Et Zucc. Promotes Tat-Dependent HIV Latency Reversal through Triggering P-TEFb's Release from 7SK snRNP.
    Wang C; Yang S; Lu H; You H; Ni M; Shan W; Lin T; Gao X; Chen H; Zhou Q; Xue Y
    PLoS One; 2015; 10(11):e0142739. PubMed ID: 26569506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toxicity and in vitro activity of HIV-1 latency-reversing agents in primary CNS cells.
    Gray LR; On H; Roberts E; Lu HK; Moso MA; Raison JA; Papaioannou C; Cheng WJ; Ellett AM; Jacobson JC; Purcell DF; Wesselingh SL; Gorry PR; Lewin SR; Churchill MJ
    J Neurovirol; 2016 Aug; 22(4):455-63. PubMed ID: 26727904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
    Mousseau G; Kessing CF; Fromentin R; Trautmann L; Chomont N; Valente ST
    mBio; 2015 Jul; 6(4):e00465. PubMed ID: 26152583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reactivation of latent HIV-1 by inhibition of BRD4.
    Zhu J; Gaiha GD; John SP; Pertel T; Chin CR; Gao G; Qu H; Walker BD; Elledge SJ; Brass AL
    Cell Rep; 2012 Oct; 2(4):807-16. PubMed ID: 23041316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The KAT5-Acetyl-Histone4-Brd4 axis silences HIV-1 transcription and promotes viral latency.
    Li Z; Mbonye U; Feng Z; Wang X; Gao X; Karn J; Zhou Q
    PLoS Pathog; 2018 Apr; 14(4):e1007012. PubMed ID: 29684085
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Trade-off between synergy and efficacy in combinations of HIV-1 latency-reversing agents.
    Gupta V; Dixit NM
    PLoS Comput Biol; 2018 Feb; 14(2):e1006004. PubMed ID: 29451894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.